Pharmaceutical giant Eli Lilly (LLY) has reached an agreement to purchase biopharmaceutical company Morphic (MORF) in a deal valued at $3.2 billion. This...
) in a deal valued at $3.2 billion. This strategic move marks a notable expansion in Eli Lilly 's portfolio and research capabilities .To Eli Lilly and also shares of Morphic here this morning, Eli Lilly is right around the flat line after agreeing to buy Bio Pharmaceutic Biopharmaceutical Company , Morphic, a $3.2 billion deal.Really seeing the action play out in shares of Morphic, they're up just around 75% right now.
We know that they've already gotten one drug in the same category approved last year and they're looking at this to sort of boost other areas as well including cancer.We do know that morphic, of course, with being a small biotech, of course, those uh th that stock is up quite significantly.I know everyone's watching that part of the stock.
The amount Hindenburg Research made from it's short-seller report on Adani Group pales in comparison to the market value it erased.The farm-equipment manufacturer will lay off about 600 employees across three US factories as it shifts production to a newly planned facility in Ramos, Mexico.Barron’s found seven candidates—that aren’t the six tech giants—that have improving Wall Street sentiment, increasing earnings estimates, and haven’t substantially outperformed the market.
"Two years ago, workers who lost their jobs could simply walk across the street to find new work. That has become increasingly difficult," BCA said.NEW YORK — The entertainment giant Paramount will merge with Skydance, closing out a decades long run by the Redstone family in Hollywood and injecting desperately needed cash into a legacy studio that has struggled to adapt to a shifting entertainment landscape.
Is the $1M nest egg irrelevant? 81% of retirees 65-plus with $50K-$100K in savings say they're living decently
Biopharmaceutical Company Research Capabilities Anjalee Khemlani
Canada Latest News, Canada Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly to buy bowel disease drug developer Morphic for US$3.2-billionThe acquisition gives Eli Lilly access to an experimental drug for types of inflammatory bowel diseases
Read more »
Lilly Agrees to Buy US Biotech Morphic in $3.2 Billion Deal(Bloomberg) -- Eli Lilly & Co. agreed to buy U.S. biopharma company Morphic Holding Inc. for about $3.2 billion to gain experimental therapies for...
Read more »
Lilly agrees to buy U.S. biotech Morphic in US$3.2 billion dealEli Lilly & Co. agreed to buy U.S. biopharma company Morphic Holding Inc. for about US$3.2 billion to gain experimental therapies for inflammatory bowel disease and other chronic illnesses.
Read more »
Innovent’s Obesity Drug Shows Similar Weight Loss as Eli Lilly’sA new obesity drug co-developed by China’s Innovent Biologics Inc. and Eli Lilly & Co. has demonstrated significant weight loss in a late stage trial, paying the way for its approval in the country to compete with the blockbuster from Novo Nordisk A/S.
Read more »
Novo Nordisk, Eli Lilly still top 2 pharma stocks: AnalystNovo Nordisk (NVO) and Eli Lilly (LLY) both made headlines recently with positive drug trial results for their respective GLP-1 weight-loss drugs, as well as...
Read more »
Eli Lilly unveils new North Carolina plant for GLP-1 drugsEli Lilly and Company (LLY) unveiled a new manufacturing plant in North Carolina on Friday, which, according to the pharmaceutical giant, is expected to...
Read more »